GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (STU:PH4) » Definitions » Net Income From Continuing Operations

CStone Pharmaceuticals (STU:PH4) Net Income From Continuing Operations : €-100.24 Mil (TTM As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. CStone Pharmaceuticals's net income from continuing operations for the six months ended in Jun. 2023 was €-26.97 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was €-100.24 Mil.

CStone Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for CStone Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CStone Pharmaceuticals Net Income From Continuing Operations Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial -296.22 -153.48 -266.79 -122.23 -47.16

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -159.27 -51.09 -73.27 -26.97 -

CStone Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-100.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CStone Pharmaceuticals (STU:PH4) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (STU:PH4) » Definitions » Net Income From Continuing Operations
Comparable Companies
HKSE:01244 HKSE:01873 HKSE:01167 HKSE:06622 HKSE:02496 HKSE:06978 HKSE:01672 HKSE:02181 HKSE:02256 HKSE:02137 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CSPHF:USA 02616:Hong Kong
Address
218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123
Website
https://www.cstonepharma.com
CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

CStone Pharmaceuticals (STU:PH4) Headlines

No Headlines